Amolyt Pharma
Écully
About Amolyt Pharma
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $311.3M
- Funding stage: M&A
- Last round: Series C (Jan 2023)
- Website: amolytpharma.com
- Phone: 33 428 01 21 54
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Wellness
Social Profiles
Canonical: https://fsome.com/organization/amolyt-pharma-107338 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.